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estimate was based on prevalence data for URDs for which patented drugs are cur-
rently available and for which drugs are in clinical development and hence may 
be expected to be launched in the foreseeable future. A power function was used 
to estimate the relation between (decreasing) prevalence and (increasing) cost per 
patient. For drugs in development, we applied phase duration data and attrition 
rates from the Tufts Center for the Study of Drug Development database. Results: 
A total of 18 drugs under patent protection for non-oncological URDs were identi-
fied. Furthermore, 29 drugs for non-oncological URDs under development that have 
the potential of reaching the market by 2021 were found. Total budget impact over 10 
years was estimated to be € 14,112 and € 4,965 million for approved and pipeline URD 
drugs, respectively (total: € 19,077 million). Relative to total pharmaceutical expendi-
tures in Europe, spending on drugs for URDs is estimated to rise from 0.7% at present 
to 1.6% in 2021. Univariate sensitivity analyses and extreme scenario analyses sug-
gesting robustness of this projection will be presented. ConClusions: Our analysis 
does not support concerns regarding an uncontrolled growth in expenditures for 
drugs for URDs. Nevertheless, continuous monitoring of the budget impact as an 
input to rational policy making is recommended.
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Budget ImPact of orPhan drugS In the netherlandS In the PerIod 
2006-2012
Kanters T.A., Steenhoek A., Hakkaart L.
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objeCtives: The relatively low budget impact of orphan drugs is often used as 
an argument in reimbursement decisions. However, overall, the budget impact of 
orphan drugs can still be substantial. In this study, we assess the uptake and budget 
impact of orphan drugs in the Netherlands. Methods: We examined the number 
of orphan drugs, the number of patients and budget impact of orphan drugs in the 
Netherlands in the period 2006 to 2012, both for inpatient and outpatient orphan 
drugs. Budget impact was provided in absolute numbers and relative to total phar-
maceutical spending. Results: The number of orphan drugs and patients treated 
increased substantially over the period studied. Overall, budget impact increased 
substantially over a period of six years, both in absolute terms (426% increase) as 
well as relative to total pharmaceutical spending (378% increase). Growth rates 
decreased over time. In 2012, 17% of available drugs had an individual budget impact 
of more than € 10 million per year. ConClusions: Individual budget impact of 
orphan drugs is often limited, although exceptions exist. However, in total, the 
budget impact of orphan drugs is considerable and has grown substantially over 
the years. This could potentially influence reimbursement decisions for orphan 
drugs in the future.
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objeCtives: Biosimilar infliximab has been approved by EMA for the management 
of inflammatory autoimmune disorders including rheumatoid arthritis (RA), anky-
losing spondylitis (AS), Crohn’s disease, ulcerative colitis (UC), psoriatic arthritis 
(PsA), and psoriasis based on quality, safety and efficacy profiles comparable to inf-
liximab. The aim of this study was to evaluate the five-year budget impact of intro-
ducing biosimilar infliximab in the management of RA, AS, Crohn’s disease, UC, PsA, 
and psoriasis from the health care system perspective. Methods: An Excel-based 
budget impact model was developed. The numbers of patients eligible for infliximab 
were calculated based on disease prevalence rates in Germany, Italy, Belgium, the 
Netherlands and the United Kingdom. The price of biosimilar infliximab is not yet 
known; therefore three discount scenarios versus infliximab (10%, 20%, and 30%) 
were applied. Market share was assumed to be 25% in the first year in all scenarios. 
Annual market share growth was varied in each of the scenarios at 20%, 30% and 
40%, respectively. Results: The combined net budget savings for Germany, Italy, 
Belgium, the Netherlands and the United Kingdom in the first year were € 17.8, € 35.5 
and € 53.3 million for the 10%, 20% and 30% price discount scenarios, respectively. 
Over a 5 year period the net budget savings were € 132.8, € 322.8 and € 532.8 million 
for the 10%, 20% and 30% price discount scenarios, respectively. ConClusions: 
The introduction of biosimilar infliximab as a treatment option for patients with RA, 
AS, Crohn’s disease, UC, PsA, and psoriasis could achieve substantial cost savings 
for health care systems. In the price discount scenarios tested, the total combined 
savings across Germany, Italy, Belgium, the Netherlands and the United Kingdom 
over a 5 year period ranged from € 132.8 million to € 532.8 million. The net budget 
impact was highly sensitive to market uptake rates and the price discount applied.
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objeCtives: To estimate budget impact analysis (BIA) of belimumab plus stand-
ard of care (SoC) comparing the SoC alone in the treatment of patients suffering 
from systemic lupus erythematosus (SLE). Methods: BIA was conducted of the 
belimumab treatment plus SoC vs SoC alone. Costs of treatments in both groups 
contained following direct medical costs: costs of drugs and administration, costs 
of diagnostic laboratory and instrumental procedure, costs of inpatient and outpa-
tient visits, costs of SLE complications and also adverse event costs. A five-year time 
horizon was used. All costs in both groups were estimated to their present value 
using a 5 % discount rate. Results: Costs of the course of belimumab therapy were 
2,118,449 RUB/ 45,581 EUR for 5 years but the difference in the required budget funds 
between belimumab treatment groups and SoC alone treatment group amounted to 
1,876,965 RUB/ 40,385 EUR for 5 years with a 5 % discount rate. The decrease of the 
difference in the required budget funds between these two groups was due to a lower 
so. Results: Our 1. hypothesis, that the children with normal weight move much, 
than their obese companions, not proven true (p= 0,778). It was the next supposition 
that less are truth with a subject for the students with normal weight they have 
difficulties, than for the obese students. According to the examination, the normal 
one and the obese child with a subject truth in the look of difficulty, we found a 
significant difference (p= 0,015). The third hypothesis, that, in the obese group taller 
the anxious children’s proportion, than the did not grow fat in a group, not proven 
true. The overweight children (n= 46, medium= 109, 76) anxiety with a significantly 
bigger degree was not showed based on the scale the normal one tápláltsági state 
at students (n= 95, medium= 104, 56 dot, p= 0,515). ConClusions: The enrolled 
students showed no significant difference between the observed parameters of the 
overweight and sporting habits.
SYStemIc dISorderS/condItIonS – cost Studies
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objeCtives: Bispectral Index (BIS) monitoring systems monitor spontaneous elec-
troencephalography, track sedative drug effects and help guide anaesthetic admin-
istration. Evidence shows such monitoring enables savings on anaesthesia and 
reduces adverse events compared with monitoring clinical signs only. However, the 
cost-effectiveness of monitors is uncertain. Methods: A cost-effectiveness model 
and budget impact analysis were developed to compare the outcomes of monitor-
ing the depth of anaesthesia with BIS monitors compared with standard clinical 
monitoring. Over a five-year period, the model estimated the incremental cost per 
quality-adjusted life year (QALY) and incremental number of adverse events avoided 
in theatres with anaesthetists using BIS monitors compared with standard care. 
Data values were obtained from peer-reviewed literature. Subgroup analysis was 
conducted for an elderly patient group. Sensitivity analyses explored uncertainty 
in the model. A budget impact model examined the financial impact of adopting 
BIS monitors across the UK. Results: The modelled results showed that using BIS 
monitors dominated clinical observation of signs and use of electrocardiograph 
and other devices, being cost saving by £82 per operation in the adult population, 
whilst improving QALYs by 0.016 per patient. The budget impact analysis showed 
a cumulative saving of over £136 million if theatres in the UK adopted a phased 
increase in monitor use such that 1.35 million surgical procedures were conducted 
using these monitors in five years time. ConClusions: Adopting BIS monitors 
is cost-effective and results in substantial cost savings compared with observing 
clinical signs plus conventional devices only.
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objeCtives: To estimate the costs of drug supply for registered rare diseases (RD) 
patients in Russia in 2013. Methods: The study included two steps: 1) the analysis 
of the current situation with financing of drugs for RD patients in Russia in 2013 
and 2) estimating the unmet needs - necessary weighted average costs (nWAC) for 
a pathogenetic pharmacotherapy of registered patients with RD in the same year. 
Number of registered patients with 24 RD listed in the Government Regulation of 
Russian Federation № 403 from April 26, 2012 was estimated for the studied year. 
Number of registered patients and actual financing has been received from the 
database of regional public health services. The nWAC for expensive pathogenetic 
pharmacotherapy of patients with 24 RD were calculated on the basis of stand-
ards of therapy and experts’ survey results. The current situation with financing 
of RD drugs in Russia in 2013 was compared with unmet needs (nWAC). Results: 
4.4 billion rubles ($125.7 million) were spent from regional budgets in Russia for 
11,173 patients (0.008% from all population of Russia) with 24 RD in 2013. The larg-
est patient group with 3,460 patients was a classic phenylketonuria group. The 
prognostic annual nWAC for pharmacotherapy of the most expensive patient with 
type VI mucopolysaccharidosis were 40.9 million rubles ($1.2 million) per child 
and 71.5 million rubles ($2.0 million) per adult. The nWAC for pharmacotherapy 
of registered patients with 24 RD in 2013 were 15.7 billion rubles ($448.6 million). 
The annual nWAC for pharmacotherapy of the most expensive disease (idiopathic 
thrombocytopenic purpura (Evans syndrome) was estimated as 2.9 billion rubles 
($82.8 million) per group of 2,700 patients. ConClusions: The state financing of 
pharmacotherapy for patients with 24 RD in Russia should be increased approxi-
mately in 3.5 times to fulfill the unmet needs.
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Budget ImPact analYSIS of drugS for ultra-rare non-oncologIcal 
dISeaSeS In euroPe
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objeCtives: Ultra‐rare disorders (URDs) have been defined by a prevalence of less 
than 1 per 50,000 persons. On a per patient basis, the annual acquisition costs of 
drugs for URDs can be very high, and there have been concerns that expenditures 
for these products might escalate in the future. The goal of this study was therefore 
to provide a budget impact analysis (BIA) of drugs for ultra-rare non-oncological 
diseases in Europe. Methods: The BIA had a time horizon of 10 years (from 2012 
to 2021) and adopted the perspective of all European payers in combination. The 
A526  VA L U E  I N  H E A LT H  1 7  ( 2 0 1 4 )  A 3 2 3 – A 6 8 6  
was calculated. Considering a switch to aztreonam lysine, the reduction of exacerba-
tion was estimated in order to maintain the overall treatment cost. For the base case, 
ex-factory prices were considered; for sensitivity analysis, discounts ranged from 15 
to 50%. Results: Switching to aztreonam lysine would not increase overall treatment 
costs in 8/12 options; even maintaining current exacerbation episodes could lead to 
SNS savings. In the remaining options, the required reduction of exacerbations var-
ies depending on the patient’s current situation, ranging from 110% (one episode/
year) to 18% (six episodes/year). In the sensitivity analysis, there are 3 options in 
which switching to aztreonam lysine would not imply higher treatment costs. For the 
remaining alternatives, the required reduction of exacerbations does not change 
significantly from the base case: from 116% (one episode/year) to 19% (six episodes/
year). ConClusions: In CF patients with chronic pulmonary infection by PA, hos-
pitalizations costs due to exacerbations have a greater economic impact than drug 
treatment costs. Using aztreonam lysine, instead of other treatments, would not imply 
a budget impact in a wide range of patient profiles if exacerbation episodes can be 
reduced. As the number of current exacerbations increases, a lesser reduction of these 
events is required by a switch to aztreonam lysine to avoid incremental treatment costs.
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ImPact of generIc SuBStItutIon on the PreScrIBIng of meProBamate-
contaInIng comBInatIon analgeSIcS In South afrIca
Truter I.
Nelson Mandela Metropolitan University, Port Elizabeth, South Africa
objeCtives: Meprobamate is a constituent of various combination analgesics in 
South Africa. Due to its abuse potential, the scheduling status of meprobamate is 
currently under review with the possibility of introducing stricter controls on its 
availability. The primary aim was to determine the impact of generic substitution on 
meprobamate-containing combination analgesic prescribing. Methods: A retro-
spective, cross-sectional drug utilisation study was conducted on prescription data 
of a medical insurance scheme administrator in South Africa for 2011. Results: A 
total of 97 491 analgesics were dispensed to 31 854 patients during the year. Within 
ATC category N02B, 62.10% of prescriptions were for analgesic combinations, of 
which 20 326 prescriptions were for meprobamate-containing analgesics at a cost 
of R282 930. A total of 10 404 patients received meprobamate-containing analgesics. 
Overall, 20.85% of all analgesics contained meprobamate. Patients who received 
meprobamate-containing analgesics were slightly older (39.52 years) compared 
to patients who received analgesics in general (33.61 years). Mandatory generic 
substitution exists in South Africa, unless otherwise indicated by the prescriber 
or if the patient refuses. Twenty-two trade names of meprobamate-containing 
analgesics were dispensed, of which 17 (the originator plus 16 branded generics) 
contained exactly the same dosages of active ingredients (320 mg paracetamol, 
8 mg codeine phosphate, 32 mg caffeine and 150 mg meprobamate). In previous 
studies, the originator product was the most often prescribed, yet in this study 
the originator product only constituted 3.72% of products prescribed (average cost: 
R30.42) compared to 70.63% for the most popular branded generic (average cost: 
R11.65). ConClusions: The price difference between generic equivalents and the 
originator product, together with mandatory generic substitution, were responsible 
for the change in prescribing patterns.
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objeCtives: The objective was to estimate the economic burden of B-thalassemia 
and to compare the cost of alternative iron chelation strategies in patients with 
transfusion (TDT) and non-transfusion dependent thalassemias (NTDT) in 
Greece. Methods: A multicenter, non interventional, retrospective, observational, 
phase IV study was conducted in the 3 out of 8 thalassemia units in Attica. Patients’ 
data and resource use, including medication and related consumables, blood trans-
fusions, lab tests, diagnostic examinations and hospital visits were recorded from 
January 2009 to December 2011, and classified per diagnosis and iron chelation treat-
ment strategies. Greek NHS perspective was considered. Results: 331 thalassemic 
patients were recorded whereas the majority (87.6%) was diagnosed with Beta-
thalassemia major, 31% were treated with deferasirox (DFX), 23% with deferoxamine 
and deferiprone, (DFO+DFP), 9.7% with deferiprone (DFP) and 5.1% with DFO. Patient 
mean annual cost per patient was € 32,064, including all treatment strategies, for 
the period 2009-2011, ranging from € 30,997 in 2009 to € 32,564 in 2011. Medication 
(45.9%), blood transfusions (38.1%) and consumables (14.9%) were the most impor-
tant cost drivers. Mean cost per patient treated with DFX was estimated at € 35,928, 
with DFO+DFP at € 34,035, with DFO at € 31,637 and with DFP at € 17,208 for the same 
period. DFX significantly reduced (p< 0.001) the number of blood transfusions in 
relation to DFO+DFP with 19 and 25 transfusions per year, respectively. Similarly, 
DFX significantly reduced the volume of blood transfusions (p< 0.001) in relation 
to DFO with 9,693ml and 10.312ml per year, respectively. ConClusions: Rational 
health care decision making process should be based on the holistic perspective of 
analytical resource use and disease management data rather than focusing on the 
price per product per se. Especially in Greece, a country where Beta-thalassemia 
incidence in general population is ~8 %, the consideration of all cost components 
should be taken into account in health resource allocation.
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frequency of inpatient visits and pulmonary, cardiovascular, renal and skin complica-
tions of SLE in group treated with belimumab. Therefore the use of belimumab led 
to a reduced difference in the required budget funds from 2,118,449 RUB/ 45,581 EUR 
to 1,876,965 RUB/ 40,385 EUR and the reduction ran as high as 241,484 RUB/ 5,196 
EUR for 5 years. ConClusions: The use of belimumab in the treatment of patients 
with SLE resulted in budget spending. However, a good safety profile and efficacy of 
belimumab help reduce the costs for 241,484 RUB/ 5,196 EUR for 5 years in belimumab 
treatment group.
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PuBlIc exPendIture on authorISed orPhan drugS In the czech 
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objeCtives: The aim of the study was to determine public expenditure on medicines 
for rare diseases from the public health sector in the Czech Republic (CZ). Methods: 
We identified orphan medicinal products (OMPs) registered by the European 
Medicines Agency (EMA) until December 2013 in the public database of EMA. In the 
base-case scenario, medicinal products available in the CZ were considered OMPs 
only within the interval of marketing authorisation date and December 2013 or OMP 
designation withdrawal date or date of withdrawal of use. Reports on consumption 
and real expenditures of these OMPs came from all health insurance companies in 
the CZ. Exchange rate of 25.4 CZK = 1 EUR was used. Results: Overall, 86 OMPs were 
authorised within the European Union (EU) between 2008 and 2013. Of these, 50 OMPs 
(58.0%) were covered from the Czech public health insurance at some point within 
this period. The number of registered OMPs increased from 54 in 2008 to 84 in 2013, 
while the number of covered OMPs doubled from 24 to 41, respectively. The annual 
public expenditure on OMPs rose simultaneously from 43 to 72 million EUR, while 
the total expenditure on drugs increased from 1.7 to 2.0 billion EUR. The OMP share of 
total pharmaceutical sales grew steadily from 2.5% in 2008, reaching 3.4% in 2011 and 
plateaued at 3.6% in 2013. Twenty-one oncological OMPs (51.2%) generated up to 72.6% 
of the overall orphan costs in 2013. ConClusions: Compared to other EU countries, 
the Czech public expenditure on OMPs of 3.6% of all drugs seems to be relatively high. 
The major part of OMP costs is in oncological diagnoses. One of the limitations is the 
exclusion of designated OMPs not authorised by EMA since these OMPs still might 
be present on the market and reimbursed. This aspect needs further investigation.
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objeCtives: The objective of this analysis was to estimate and compare the annual 
cost per patient of the administration of capsaicin 8% patch, Qutenza®, in Primary 
and Secondary Care for the treatment of adult patients with peripheral neuropathic 
pain (PNP). The annual cost per patient treated with Qutenza® was also compared 
with Pregabalin and Lidocaine in Primary Care. Methods: The costs per patient 
for each treatment were estimated by analysing the health care resources associ-
ated with the use of pregabalin, lidocaine and Qutenza®for the treatment of PNP 
from the perspective of the Spanish National Health System. Healthcare resources 
associated with the three pharmacological treatments considered were admin-
istration time and health care personnel, complementary non-pharmacological 
treatment, hospitalisation, adverse effects and concomitant medication, EUR 2013. 
Total costs per patient were estimated and compared both including and excluding 
concomitant medication to estimate the effect on the treatment costs. Results: 
The annual treatment cost per patient when Qutenza® is administrated in the hos-
pital was estimated at € 5,387.32 and € 5,259.19 when administered in Primary Care. 
Qutenza® applied in Primary Care for the treatment of PNP showed annual savings 
of € 128.14 per patient compared with the administration of Qutenza® in Secondary 
Care. Overall, the annual treatment costs per patient with pregabalin or lidocaine 
were estimated at € 14,074.14 and € 5,998.09, respectively, resulting in savings of 
€ 8,814.95 and € 738.9 respectively when compared with the annual cost per patient 
when treated with Qutenza® in Primary Care. ConClusions: The introduction 
of Qutenza® into Primary Care for the treatment of PNP is expected to result 
in annual savings due to lower administration costs associated with the use of 
Qutenza® and savings in health care personnel in Primary Care. Qutenza® also 
showed to be the less expensive option in comparison with pregabalin or lidocaine, 
independent of the area of administration.
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a treatment regIme WIth Inhaled antIBIotIcS IS SWItched to 
aztreonam lYSIne In PatIentS WIth cYStIc fIBroSIS and chronIc 
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objeCtives: Estimate, from the Spanish National Healthcare System (SNS) perspec-
tive, the required reduction of exacerbation episodes in different patient profiles to 
maintain constant the overall treatment cost if a chronic treatment with inhaled anti-
biotics is switched to aztreonam lysine in patients with cystic fibrosis (CF) and chronic 
pulmonary infection by Pseudomonas aeruginosa (PA). Methods: A cost comparison 
model was developed considering two criteria to define patient profiles: current drug 
treatment (12 options linked to tobramycin and/or colistimethate sodium) and current 
exacerbation episodes (1-6/year). For each patient profile the overall treatment cost 
